Limits...
Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival.

Desurmont T, Skrypek N, Duhamel A, Jonckheere N, Millet G, Leteurtre E, Gosset P, Duchene B, Ramdane N, Hebbar M, Van Seuningen I, Pruvot FR, Huet G, Truant S - Cancer Sci. (2015)

Bottom Line: By multivariate analysis, CXCR2 and CXCL7 expressions are independent factors of overall and disease-free survival.CXCL7 was overexpressed close to significance, 0.40 (0.00-7.85) vs 0.15 (0.01-7.88), P = 0.12.Selective blockage of CXCR2/CXCL7 signalling pathways could provide new potential therapeutic opportunities.

View Article: PubMed Central - PubMed

Affiliation: Inserm, U837, Team-5 (Mucins, Epithelial Differentiation, and Carcinogenesis), Jean-Pierre Aubert Research Centre, Université Lille, France; Department of Digestive and Visceral Surgery, GHICL, Saint-Vincent de Paul Hospital, Lille, France.

Show MeSH

Related in: MedlinePlus

Comparison of chemokine and chemokine receptor transcript levels in liver metastases from patients treated or not treated with neoadjuvant chemotherapy prior to hepatic surgery. (a) CXCR2 expression. (b) CXCL7 expression. (c) CXCL8 expression. (d) Synthesis of results for CXCR2, CXCR4, CXCL7, and CXCL8 expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4376434&req=5

fig02: Comparison of chemokine and chemokine receptor transcript levels in liver metastases from patients treated or not treated with neoadjuvant chemotherapy prior to hepatic surgery. (a) CXCR2 expression. (b) CXCL7 expression. (c) CXCL8 expression. (d) Synthesis of results for CXCR2, CXCR4, CXCL7, and CXCL8 expression.

Mentions: We compared the median CXCR2 expression levels in the two subgroups of patients having received, or not received, a neoadjuvant chemotherapy regimen. The median CXCR2 expression was more than threefold higher in the treated group (n = 30) than in the control group (n = 21) (1.89 [0.02–50.92] vs 0.55 [0.07–3.22], respectively; P = 0.016) (Fig.2a). Median CXCL7 expression was nearly threefold higher in the treated group than in the control group (0.40 [0.00–7.85] vs 0.15 [0.01–7.88], respectively) but without reaching statistical significance (P = 0.127) (Fig.2b). Neoadjuvant chemotherapy did not impact the median CXCL8 expression level (Fig.2c). In addition, no significant difference was found between median CXCL2, CXCL6, and MIF expression levels between the two subgroups of patients. Also contrasting with our previous findings obtained with a series of 23 patients,7 we could not confirm an increase in CXCR4 expression in treated versus untreated patients with this larger series of 55 patients (Fig.2c).


Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival.

Desurmont T, Skrypek N, Duhamel A, Jonckheere N, Millet G, Leteurtre E, Gosset P, Duchene B, Ramdane N, Hebbar M, Van Seuningen I, Pruvot FR, Huet G, Truant S - Cancer Sci. (2015)

Comparison of chemokine and chemokine receptor transcript levels in liver metastases from patients treated or not treated with neoadjuvant chemotherapy prior to hepatic surgery. (a) CXCR2 expression. (b) CXCL7 expression. (c) CXCL8 expression. (d) Synthesis of results for CXCR2, CXCR4, CXCL7, and CXCL8 expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4376434&req=5

fig02: Comparison of chemokine and chemokine receptor transcript levels in liver metastases from patients treated or not treated with neoadjuvant chemotherapy prior to hepatic surgery. (a) CXCR2 expression. (b) CXCL7 expression. (c) CXCL8 expression. (d) Synthesis of results for CXCR2, CXCR4, CXCL7, and CXCL8 expression.
Mentions: We compared the median CXCR2 expression levels in the two subgroups of patients having received, or not received, a neoadjuvant chemotherapy regimen. The median CXCR2 expression was more than threefold higher in the treated group (n = 30) than in the control group (n = 21) (1.89 [0.02–50.92] vs 0.55 [0.07–3.22], respectively; P = 0.016) (Fig.2a). Median CXCL7 expression was nearly threefold higher in the treated group than in the control group (0.40 [0.00–7.85] vs 0.15 [0.01–7.88], respectively) but without reaching statistical significance (P = 0.127) (Fig.2b). Neoadjuvant chemotherapy did not impact the median CXCL8 expression level (Fig.2c). In addition, no significant difference was found between median CXCL2, CXCL6, and MIF expression levels between the two subgroups of patients. Also contrasting with our previous findings obtained with a series of 23 patients,7 we could not confirm an increase in CXCR4 expression in treated versus untreated patients with this larger series of 55 patients (Fig.2c).

Bottom Line: By multivariate analysis, CXCR2 and CXCL7 expressions are independent factors of overall and disease-free survival.CXCL7 was overexpressed close to significance, 0.40 (0.00-7.85) vs 0.15 (0.01-7.88), P = 0.12.Selective blockage of CXCR2/CXCL7 signalling pathways could provide new potential therapeutic opportunities.

View Article: PubMed Central - PubMed

Affiliation: Inserm, U837, Team-5 (Mucins, Epithelial Differentiation, and Carcinogenesis), Jean-Pierre Aubert Research Centre, Université Lille, France; Department of Digestive and Visceral Surgery, GHICL, Saint-Vincent de Paul Hospital, Lille, France.

Show MeSH
Related in: MedlinePlus